{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:25:50Z","timestamp":1789349150297,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,4,13]],"date-time":"2008-04-13T00:00:00Z","timestamp":1208044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1136\/ard.2007.076760","type":"journal-article","created":{"date-parts":[[2008,4,14]],"date-time":"2008-04-14T15:22:42Z","timestamp":1208186562000},"page":"367-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients"],"prefix":"10.1016","volume":"68","author":[{"given":"N J","family":"Goodson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Brookhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D P M","family":"Symmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Silman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D H","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.076760_bib1","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","article-title":"Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.","volume":"107","author":"Solomon","year":"2003","journal-title":"Circulation"},{"key":"10.1136\/ard.2007.076760_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/art.20853","article-title":"Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.","volume":"52","author":"Maradit-Kremers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.076760_bib3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.20878","article-title":"Cardiovascular death in rheumatoid arthritis: a population-based study.","volume":"52","author":"Maradit-Kremers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.076760_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/art.22094","article-title":"Antirheumatic drug use and the risk of acute myocardial infarction.","volume":"55","author":"Suissa","year":"2006","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard.2007.076760_bib5","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1186\/ar2045","article-title":"Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.","volume":"8","author":"van Halm","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2007.076760_bib6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ard.2007.076760_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0149-2918(03)90003-8","article-title":"The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents.","volume":"25","author":"Armstrong","year":"2003","journal-title":"Clin Ther"},{"key":"10.1136\/ard.2007.076760_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2165\/00003495-200363060-00001","article-title":"Nonsteroidal anti-inflammatory drugs and heart failure.","volume":"63","author":"Bleumink","year":"2003","journal-title":"Drugs"},{"key":"10.1136\/ard.2007.076760_bib9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/archinte.162.10.1105","article-title":"Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.","volume":"162","author":"Watson","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1136\/ard.2007.076760_bib10","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.076760_bib11","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","article-title":"Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.","volume":"364","author":"Juni","year":"2004","journal-title":"Lancet"},{"key":"10.1136\/ard.2007.076760_bib12","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","article-title":"cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.","volume":"296","author":"McGettigan","year":"2006","journal-title":"JAMA"},{"key":"10.1136\/ard.2007.076760_bib13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/rheumatology\/33.8.735","article-title":"The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register.","volume":"33","author":"Symmons","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.076760_bib14","unstructured":"World Health Organization,. International classification of diseases, 9th revision. Geneva, Switzerland: World Health Organisation, 1977."},{"key":"10.1136\/ard.2007.076760_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.1200","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.","volume":"15","author":"Schneeweiss","year":"2006","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"10.1136\/ard.2007.076760_bib16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","article-title":"Celecoxib for the prevention of sporadic colorectal adenomas.","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.076760_bib17","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.076760_bib18","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","article-title":"Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.","volume":"352","author":"Nussmeier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.076760_bib19","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","article-title":"Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.","volume":"330","author":"Hippisley-Cox","year":"2005","journal-title":"BMJ"},{"key":"10.1136\/ard.2007.076760_bib20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.165.9.978","article-title":"Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs \u2013 a population-based case-control study.","volume":"165","author":"Johnsen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1136\/ard.2007.076760_bib21","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/CIRCULATIONAHA.105.595793","article-title":"Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events.","volume":"113","author":"Chan","year":"2006","journal-title":"Circulation"},{"key":"10.1136\/ard.2007.076760_bib22","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1161\/CIRCULATIONAHA.106.616219","article-title":"Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.","volume":"113","author":"Gislason","year":"2006","journal-title":"Circulation"},{"key":"10.1136\/ard.2007.076760_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1067\/mhj.2002.121270","article-title":"Nonsteroidal antiinflammatory drugs after acute myocardial infarction.","volume":"143","author":"Ko","year":"2002","journal-title":"Am Heart J"},{"key":"10.1136\/ard.2007.076760_bib24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.amjmed.2005.10.056","article-title":"Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs.","volume":"119","author":"Salpeter","year":"2006","journal-title":"Am J Med"},{"key":"10.1136\/ard.2007.076760_bib25","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/art.21204","article-title":"Baseline C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis.","volume":"52","author":"Goodson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.076760_bib26","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/1529-0131(200105)44:5<1170::AID-ANR200>3.0.CO;2-T","article-title":"Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians.","volume":"44","author":"Jacobsson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.076760_bib27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ncpcardio0214","article-title":"Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk \u2013 where are we now?","volume":"2","author":"Spektor","year":"2005","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1136\/ard.2007.076760_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/1568006054553381","article-title":"Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis?","volume":"5","author":"Paramo","year":"2005","journal-title":"Curr Drug Targets Cardiovasc Haematol Disord"},{"key":"10.1136\/ard.2007.076760_bib29","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1161\/01.CIR.0000124715.27937.78","article-title":"Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.","volume":"109","author":"Capone","year":"2004","journal-title":"Circulation"},{"key":"10.1136\/ard.2007.076760_bib30","first-page":"89","article-title":"Comparative antiplatelet activity of COX1 NSAIDS versus aspirin, encompassing regimen simplification and gastroprotection: a call for a controlled study.","volume":"56","author":"Rothschild","year":"2004","journal-title":"Reumatismo"},{"key":"10.1136\/ard.2007.076760_bib31","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archinte.162.10.1099","article-title":"Nonsteroidal anti-inflammatory drug use and acute myocardial infarction.","volume":"162","author":"Solomon","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1136\/ard.2007.076760_bib32","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1136\/ard.2007.076760_bib33","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","article-title":"Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.","volume":"368","author":"Cannon","year":"2006","journal-title":"Lancet"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724425910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724425910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.076760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:50:51Z","timestamp":1739523051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724425910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0003496724425910"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.076760","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.076760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 \u00a9 Goodson et al 2009, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}